Saimir Luli

机构：Clinical Research Institute, University of Newcastle Australia, Newcastle University · ORCID：0000-0002-7510-6737

发表论文 50 篇 · 总被引 1106 次 · h-index 15

代表论文

• CXCR2 inhibition enables NASH-HCC immunotherapy (2022 · Gut · 被引 236)
• NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma (2015 · Nature Communications · 被引 178)
• FPR-1 is an important regulator of neutrophil recruitment and a tissue-specific driver of pulmonary fibrosis (2020 · JCI Insight · 被引 106)
• A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A (2017 · Molecular Therapy · 被引 85)
• Loss of Endothelial Endoglin Promotes High-Output Heart Failure Through Peripheral Arteriovenous Shunting Driven by VEGF Signaling (2019 · Circulation Research · 被引 72)
• Inhibition of lysosomal protease cathepsin D reduces renal fibrosis in murine chronic kidney disease (2016 · Scientific Reports · 被引 71)